Following the FDA’s approval of the generic version of the branded drug listed by ANDA077471, GENUS has secured immediate entry into the highly competitive market, creating significant pricing pressure on existing competitors. This launch provides GENUS with a substantial revenue stream while likely driving down the cost of therapy for healthcare systems and patients alike.